8 Questions on Managing Lung Cancer

Article

Do you know the least common site for lung cancer metastasis? How about the best test for determining distant spread of disease? Answer these questions and more.

Question 1:

Answer and Question 2 on Next Page »

The correct answer is D. PET/CT Scan

Question 2:

Answer and Question 3 on Next Page »

The correct answer is C. Spleen

Question 3:

Answer and Question 4 on Next Page »

The correct answer is D. Bone marrow biopsy

Question 4:

Answer and Question 5 on Next Page »

The correct answer is B. 13% to 40%

Question 5:

Answer and Question 6 on Next Page »

The correct answer is C. Bronchoscopy

Question 6:

Answer and Question 7 on Next Page »

The correct answer is E. Level 8

Question 7:

Answer and Question 8 on Next Page »

The correct answer is D. Edema and muscle weakness

Question 8:

Answer on Next Page »

The correct answer is B. Mediastinoscopy

 

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer

Roman Fabbricatore
October 19th 2025
Article

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC

Russ Conroy
October 19th 2025
Article

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.

Capivasertib Combo Improves rPFS in PTEN-Deficient HSPC Population

Silas Inman
October 19th 2025
Article

Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

I-DXd Yields Promising Intracranial Efficacy in ES-SCLC Population

Kristi Rosa
October 19th 2025
Article

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.